| Abstrakt: |
A recent meta-analysis conducted by researchers at Heidelberg University in Germany evaluated the performance of commercial molecular tests for thyroid nodules with indeterminate cytology (ITN). The study included 53 studies involving 6490 fine needle aspirations (FNAs) with ITN cytology and molecular diagnostics. The results showed that ThyroSeq v3 (TSv3) had the best molecular diagnostic performance, followed by ThyroSeq v2 (TSv2), Afirma gene sequencing classifier (GSC), and Afirma gene expression classifier (GEC). TSv2 was found to be superior for ruling in malignancy, while GSC was superior for ruling out malignancy. The study highlights the challenges in managing thyroid nodules with indeterminate cytology and provides valuable insights into the diagnostic accuracy of different molecular tests. [Extracted from the article] |
